(Q34132863)

31 July 2017

1 reference

title

Drug-targeting strategies in cancer therapy (English)

1 reference

31 July 2017

Huang PS

1

1 reference

31 July 2017

Oliff A

series ordinal

2

1 reference

31 July 2017

publication date

1 February 2001

1 reference

Current Opinion in Genetics & Development

31 July 2017

published in

1 reference

31 July 2017

volume

11

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

104-110

1 reference

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Toward checkmate: biology and breast cancer therapy for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Distribution characteristics of carboxymethylpullulan-peptide-doxorubicin conjugates in tumor-bearing rats: different sequence of peptide spacers and doxorubicin contents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Clinical pharmacokinetics of doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Doxorubicin represses CARP gene transcription through the generation of oxidative stress in neonatal rat cardiac myocytes: possible role of serine/threonine kinase-dependent pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Taxol in the management of cancers of the breast and the ovary

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Intensely cytotoxic anthracycline prodrugs: glucuronides

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Prostate-Specific antigen expression by various tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-437X%2800%2900164-7

7 January 2021

10.1016/S0959-437X(00)00164-7

Identifiers

DOI

1 reference

release_qe4r7pvlqzhmlashqqn6yp5mk4

31 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qe4r7pvlqzhmlashqqn6yp5mk4

24 November 2022

mapped directly with Wikidata item

1 reference